XML 19 R9.htm IDEA: XBRL DOCUMENT

Deferred Grant Income

3 Months Ended

Dec. 31, 2016

Deferred Revenue Disclosure [Abstract]

Deferred Grant Income

Note 3

Deferred Grant Income

On June 19, 2015, the Company was awarded grant funding in the amount of $286,455, of which the Company has received $214,836 and the remainder will be received in instalments over the remainder of the commitment. The grant was received in exchange for a commitment to provide research and development for preclinical validation of Sigma-1 receptor agonism as potential treatment for Parkinson’s disease.

The grant income has been deferred and is being amortized to other income over the related commitment period as the related research and development expenditures are incurred. During the three months ended December 31, 2016, the Company recognized $35,286 (2015: $39,055) of this grant on its statement of operations within grant income.

During the three months ended December 31, 2015, the Company recognized other grant income of $571,093 in respect of a research and development incentive program offered by the Australian government.

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details